In comparison to the clinically approved antiangiogenic drug bevacizumab, SST3‐Avi‐C3 exerts improved bioactivity by an alternative pathway inhibiting Rho‐dependent tumor‐associated angiogenesis at a much lower therapeutic dosage. The gene discussed is RHO; the disease is neoplasm.